PSCK9 inhibitors reduced early recurrent stroke in patients with symptomatic intracranial atherosclerotic stenosis.
Li WuBo ZhangChenghao LiZhuolin ZhuangKang LiuHualin ChenShuanggen ZhuJuehua ZhuZheng DaiHuameng HuangYongjun JiangPublished in: Journal of neurology, neurosurgery, and psychiatry (2024)
In our study, PCSK9 inhibitors add-on therapy further reduced LDL-C levels and ERS in patients with symptomatic ICAS.